Literature DB >> 18791852

Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion.

Kashif Qureshi1, Shahram Kashani, Simon P Kelly.   

Abstract

Two patients with ischaemic central retinal vein occlusion were treated with intracameral bevacizumab in order to affect the outcome of their disease. In addition, both patients underwent episodes of cycloablative and pan-retinal laser treatment. The patients were followed for more than 6 months and achieved some stability with a combination of these modalities.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18791852     DOI： 10.1007/s10792-008-9262-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN： 0165-5701            Impact factor:   2.031


  6 in total

1.  Intracameral bevacizumab for iris rubeosis.

Authors:  Salvatore Grisanti; Sabine Biester; Swaantje Peters; Olcay Tatar; Focke Ziemssen; Karl Ulrich Bartz-Schmidt
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

2.  The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.

Authors:  A E Fung; P J Rosenfeld; E Reichel
Journal:  Br J Ophthalmol       Date:  2006-07-19       Impact factor: 4.638

3.  [Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application].

Authors:  C H Meyer; S Mennel; N Eter
Journal:  Ophthalmologe       Date:  2007-11       Impact factor: 1.059

4.  Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma.

Authors:  Shahin Yazdani; Kamran Hendi; Mohammad Pakravan
Journal:  J Glaucoma       Date:  2007-08       Impact factor: 2.503

5.  Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma.

Authors:  K V Chalam; S K Gupta; S Grover; V S Brar; S Agarwal
Journal:  Eur J Ophthalmol       Date:  2008 Mar-Apr       Impact factor: 2.597

6.  Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye.

Authors:  A Raghuram; V R Saravanan; V Narendran
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
  6 in total
  3 in total

Review 1.  Nanoparticles for drug delivery to the anterior segment of the eye.

Authors:  Dileep R Janagam; Linfeng Wu; Tao L Lowe
Journal:  Adv Drug Deliv Rev       Date:  2017-04-06       Impact factor: 15.470

2.  Evaluating the safety of intracameral bevacizumab application using oxidative stress and apoptotic parameters in corneal tissue.

Authors:  Ali Akal; Turgay Ulas; Tugba Goncu; Muhammet Emin Guldur; Sezen Kocarslan; Abdullah Taskin; Hatice Sezen; Kudret Ozkan; Omer Faruk Yilmaz; Hakan Buyukhatipoglu
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

3.  Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis.

Authors:  Daisuke Sora; Kei Takayama; Manzo Taguchi; Tomohito Sato; Yutaka Sakurai; Takayuki Kanda; Masaru Takeuchi
Journal:  Case Rep Ophthalmol       Date:  2018-03-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.